The Potential of Cystatin C As a Predictive Biomarker in Pulmonary Hypertension

Overview

Journal BMC Pulm Med

Publisher Biomed Central

Specialty Pulmonary Medicine

Date 2023 Aug 26

PMID 37633906

Authors

Anqi Duan

Zhihua Huang

Zhihui Zhao

Qing Zhao

Qi Jin

Lu Yan

Yi Zhang

Xin Li

Sicheng Zhang

Meixi Hu

Luyang Gao

Chenhong An

Qin Luo

Zhihong Liu

Affiliations

Soon will be listed here.

Abstract

Background: Cystatin C is a novel biomarker to identify renal dysfunction and cardiovascular risk.

Objective: The aim of this study was to investigate the role of cystatin C in non-invasive risk prediction in a large cohort of patients with pre-capillary pulmonary hypertension (PH).

Method: We retrospectively analyzed pre-capillary PH patients with available cystatin C and hemodynamic data derived from right heart catheterization.

Results: A total of 398 consecutive patients with confirmed pre-capillary PH were recruited from Fuwai Hospital between November 2020 and November 2021. Over a median duration of 282 days, 72 (18.1%) of these patients experienced clinical worsening. Cystatin C levels significantly correlated with cardiac index (r = -0.286, P < 0.001), mixed venous oxygen saturation (r = -0.216, P < 0.001), and tricuspid annular plane systolic excursion (r = -0.236, P < 0.001), and high cystatin C levels independently predicted a poor prognosis after adjusting potential confounders in different models (all P < 0.05). A three-group non-invasive risk model was constructed based on the combined assessment of the cystatin C and WHO-FC using dichotomous cut-off value. Those patients with higher cystatin C (≥ 1.0 mg/L) and a worse WHO-FC experienced the highest risk of endpoint occurrence. The predictive capacity of this model was comparable to that of an existing invasive risk stratification model (area under curve: 0.657 vs 0.643, P = 0.619).

Conclusions: Cystatin C levels were associated with disease severity and prognosis in patients with pre-capillary PH. A combination of high cystatin C and advanced WHO-FC identifies patients at particularly high risk of clinical deterioration.

Citing Articles

Proteomic Risk Score of Increased Respiratory Susceptibility: A Multi-Cohort Study.

Liu G, Perry A, Washko G, Farber-Eger E, Colangelo L, Sheng Q Am J Respir Crit Care Med. 2024; .

PMID: 39254293 PMC: 11755364. DOI: 10.1164/rccm.202403-0613OC.

Bibliometric analysis of T-cells immunity in pulmonary hypertension from 1992 to 2022.

Chen X, Yan Z, Pan Q, Zhang C, Chen Y, Liang X Immun Inflamm Dis. 2024; 12(7):e1280.

PMID: 38967362 PMC: 11225084. DOI: 10.1002/iid3.1280.

Circulating Biomarkers in Pulmonary Arterial Hypertension: An Update.

Correale M, Tricarico L, Bevere E, Chirivi F, Croella F, Severino P Biomolecules. 2024; 14(5).

PMID: 38785959 PMC: 11117582. DOI: 10.3390/biom14050552.

Association of serum creatinine to cystatin C to waist circumference ratios and hypertension: evidence from China health and retirement longitudinal study.

Yang Y, Sun Q, Ma S, Li X, Lang X, Zhang Q Front Endocrinol (Lausanne). 2024; 15:1375232.

PMID: 38752178 PMC: 11094208. DOI: 10.3389/fendo.2024.1375232.

Correlation Between Cystatin C and the Severity of Cardiac Dysfunction in Patients with Systolic Heart Failure.

Ge J, Ji Y, Wang F, Zhou X, Wei J, Qi C Risk Manag Healthc Policy. 2023; 16:2419-2426.

PMID: 38024499 PMC: 10655600. DOI: 10.2147/RMHP.S437678.

References

Ivey-Miranda J, Inker L, Griffin M, Rao V, Maulion C, Turner J . Cystatin C and Muscle Mass in Patients With Heart Failure. J Card Fail. 2020; 27(1):48-56. PMC: 8672303. DOI: 10.1016/j.cardfail.2020.07.013. View

Cachofeiro V, Goicochea M, de Vinuesa S, Oubina P, Lahera V, Luno J . Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl. 2008; (111):S4-9. DOI: 10.1038/ki.2008.516. View

Levey A, Bosch J, Lewis J, Greene T, Rogers N, Roth D . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130(6):461-70. DOI: 10.7326/0003-4819-130-6-199903160-00002. View

Nickel N, OLeary J, Brittain E, Fessel J, Zamanian R, West J . Kidney dysfunction in patients with pulmonary arterial hypertension. Pulm Circ. 2017; 7(1):38-54. PMC: 5448543. DOI: 10.1086/690018. View

Blok I, van Riel A, Schuuring M, de Bruin-Bon R, van Dijk A, Hoendermis E . The role of cystatin C as a biomarker for prognosis in pulmonary arterial hypertension due to congenital heart disease. Int J Cardiol. 2016; 209:242-7. DOI: 10.1016/j.ijcard.2016.02.003. View

Hoeper M, Kramer T, Pan Z, Eichstaedt C, Spiesshoefer J, Benjamin N . Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017; 50(2). DOI: 10.1183/13993003.00740-2017. View

Damman K, Navis G, Smilde T, Voors A, van der Bij W, Van Veldhuisen D . Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail. 2007; 9(9):872-8. DOI: 10.1016/j.ejheart.2007.05.010. View

Aimo A, Castiglione V, Borrelli C, Saccaro L, Franzini M, Masi S . Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies. Eur J Prev Cardiol. 2019; 27(5):494-510. DOI: 10.1177/2047487319870344. View

Kashani K, Rosner M, Ostermann M . Creatinine: From physiology to clinical application. Eur J Intern Med. 2019; 72:9-14. DOI: 10.1016/j.ejim.2019.10.025. View

10.

Humbert M, Kovacs G, Hoeper M, Badagliacca R, Berger R, Brida M . 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022; 43(38):3618-3731. DOI: 10.1093/eurheartj/ehac237. View

11.

Toma M, Miceli R, Bonsante E, Colombo D, Confalonieri M, Garascia A . Left Heart Disease Phenotype in Elderly Patients with Pulmonary Arterial Hypertension: Insights from the Italian PATRIARCA Registry. J Clin Med. 2022; 11(23). PMC: 9735657. DOI: 10.3390/jcm11237136. View

12.

Sahin C, Pamukcu O . Serum Cystatin C: A Potential Biomarker in Pulmonary Hypertension in Children. Indian J Pediatr. 2023; 90(4):417. DOI: 10.1007/s12098-023-04487-y. View

13.

Breidthardt T, Sabti Z, Ziller R, Rassouli F, Twerenbold R, Kozhuharov N . Diagnostic and prognostic value of cystatin C in acute heart failure. Clin Biochem. 2017; 50(18):1007-1013. DOI: 10.1016/j.clinbiochem.2017.07.016. View

14.

Zou L, Sun L, Nicholas S, Lu Y, K S, Hua R . Comparison of bias and accuracy using cystatin C and creatinine in CKD-EPI equations for GFR estimation. Eur J Intern Med. 2020; 80:29-34. DOI: 10.1016/j.ejim.2020.04.044. View

15.

Kaiser R, Seiler S, Held M, Bals R, Wilkens H . Prognostic impact of renal function in precapillary pulmonary hypertension. J Intern Med. 2013; 275(2):116-26. DOI: 10.1111/joim.12131. View

16.

Ni H, Wei Y, Yang L, Wang Q . An increased risk of pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema: a meta-analysis. BMC Pulm Med. 2023; 23(1):221. PMC: 10283193. DOI: 10.1186/s12890-023-02425-4. View

17.

Ruaro B, Confalonieri P, Caforio G, Baratella E, Pozzan R, Tavano S . Chronic Thromboembolic Pulmonary Hypertension: An Observational Study. Medicina (Kaunas). 2022; 58(8). PMC: 9415110. DOI: 10.3390/medicina58081094. View

18.

Inker L, Eneanya N, Coresh J, Tighiouart H, Wang D, Sang Y . New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021; 385(19):1737-1749. PMC: 8822996. DOI: 10.1056/NEJMoa2102953. View

19.

van der Laan S, Fall T, Soumare A, Teumer A, Sedaghat S, Baumert J . Cystatin C and Cardiovascular Disease: A Mendelian Randomization Study. J Am Coll Cardiol. 2016; 68(9):934-45. PMC: 5451109. DOI: 10.1016/j.jacc.2016.05.092. View

20.

Bitker L, Sens F, Payet C, Turquier S, Duclos A, Cottin V . Presence of Kidney Disease as an Outcome Predictor in Patients with Pulmonary Arterial Hypertension. Am J Nephrol. 2018; 47(2):134-143. DOI: 10.1159/000487198. View